By Michael Dabaie

Johnson & Johnson's Janssen Pharmaceutical Cos. said a study of Tremfya met its primary objective in psoriatic arthritis.

The company said the latest Phase 3 data for Tremfya demonstrated significant and durable improvement in signs and symptoms of active psoriatic arthritis while maintaining its safety profile in patients with inadequate response to tumor necrosis factor inhibition.

Results showed significantly higher proportions of patients treated with Tremfya had improvement in joint signs and symptoms and complete skin clearance versus placebo at week 24. Improvements in signs and symptoms of PsA were maintained or numerically increased through one year among Tremfya-randomized patients, the company said.

Tremfya is approved in the U.S. for moderate to severe plaque psoriasis and active psoriatic arthritis.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

December 03, 2021 08:49 ET (13:49 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.